

HISTORY

A 30+ YEAR JOURNEY WITH A
RELENTLESS FOCUS ON SCIENCE

Our commitment to patients extends well beyond our labs. We are proud to support the communities we serve, to embrace a culture and business model of patients over profits and to hold the highest ethical standards when it comes to patient well-being.

Jump to year: 2020
2019
2018
2017



Regeneron is founded by
Leonard S. Schleifer, MD,
PhD, a young neurologist and
assistant professor at Cornell
University Medical College

1988

[LEN SCHLEIFER
DESCRIBES HOW
REGENERON RAISED
ITS FIRST \\$1
MILLION](#)

[LEN SCHLEIFER
EXPLAINS HOW
REGENERON GOT ITS
NAME](#)

**1989**

George D. Yancopoulos, MD,
PhD, a highly regarded young
molecular immunologist at
Columbia University, joins
Regeneron

[LEN AND GEORGE
REFLECT ON THEIR
LONG PARTNERSHIP](#)

[BACK
TO TOP](#)



Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

1990

We announce a collaboration to develop neurotrophic factors

**1991**

REGN stock begins trading publicly on the NASDAQ; the initial public offering (IPO) raises \$91.6 million



Clinical development of our first investigational drug, a neurotrophic factor, begins

1992**1993**

We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved medicine



Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

1995

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

[BACK](#)
[TO TOP](#)



1997 The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions



1999

George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

2000 Our investigational medicine rilonacept begins clinical exploration



2003

Our first paper on *VelociGene*[®] is published, introducing the world to our proprietary *Veloci* technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students



2004 Our investigational medicine aflibercept begins clinical development

[BACK TO TOP](#)



Sarilumab, our first fully human antibody, enters clinical development

2006

A collaboration with Bayer HealthCare focuses on developing aflibercept outside the U.S.

 **VELOCIMMUNE®**

2007

A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune® technology platform



The FDA approves our first medicine, **ARCALYST® (rilonacept) Injection**

2008

*In 2021, Kiniksa assumed U.S. commercial rights to ARCALYST for all approved indications

We expand and extend our antibody collaboration with Sanofi

2009

Our investigational medicine alirocumab begins clinical development

We hire our 1,000th employee and move into new buildings on our Tarrytown campus



We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

2010



[BACK TO TOP](#)

**2011**

The FDA approves [EYLEA® \(aflibercept\) Injection](#) for its first indication

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®

**2012**

The *Science* Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

2013

Our European business office opens in Dublin, Ireland



Scrip Intelligence names Len and George as the "Management Team of the Year"



The Regeneron Genetics Center®, a new human genetics initiative, officially launches

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields. [Learn more about our initiatives](#)

2014

[BACK TO TOP](#)



2015

The FDA approves **PRALUENT® (alirocumab) Injection** our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immuno-oncology collaboration with Sanofi



We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

2016



The FDA approves **DUPIXENT® (dupilumab) Injection**, our fifth FDA-approved medicine

2017



The FDA approves **KEVZARA® (sarilumab) Injection**, our sixth FDA-approved medicine and second fully human monoclonal antibody

Recognized on the **Civic 50** list of most community-minded companies in the United States



The FDA approves a new indication for **DUPIXENT® (dupilumab) Injection**



2018

The FDA approves **Libtayo® (cemiplimab-rwlc) Injection**, our seventh FDA-approved

[BACK TO TOP](#)



2019


Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education. Society for Science announces Regeneron as new sponsor of the International Science and Engineering Fair

The FDA and European Commission approves new indications for **EYLEA® (afibercept) injection**, **DUPIXENT® (dupilumab) injection**, **Libtayo® (cemiplimab) injection** and **PRALUENT® (alirocumab) injection**.

Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies.



The FDA approves an expanded indication for **DUPIXENT® (dupilumab) injection**



The FDA approves **Inmazole™ (atoltivimab, maftivimab, and odesivimab-ebgn)**

Regeneron discovers and develops a novel COVID-19 antibody cocktail in record time; the FDA authorizes it for emergency use later the same year

Regeneron named *Science* magazine's #1 biopharma company for the seventh

2020



There may be no other thing you can do that is more rewarding than to really move the human condition forward

**George D.
Yancopoulos, MD,
PhD**

[BACK
TO TOP](#)

SCIENCE TO MEDICINE®

[Terms of Use](#)

[Contact Us](#)

[Site Map](#)

[Social Media Terms of
Engagement](#)

[Privacy Notice](#)

[Accessibility Statement](#)

INVESTORS AND MEDIA

CAREERS

IRELAND

COVID-19 ANTIBODY PROGRAM

Copyright © 2021 Regeneron Pharmaceuticals Inc. All rights reserved. All trademarks mentioned are the property of their respective owners.

***BACK
TO TOP***